中國生物製藥(01177.HK)獲授權作爲派安普利單抗注射液在中國唯一銷售單位
格隆匯12月20日丨中國生物製藥(01177.HK)公告,集團與聯營公司正大天晴康方(上海)生物醫藥科技有限公司及其股東中山康方生物醫藥有限公司簽訂了派安普利單抗獨家銷售協議。
根據該協議,(i)集團獲授權作爲派安普利單抗注射液(PD-1抗體(AK105)產品,"PD-1單抗產品")在中國的唯一銷售單位,全權負責PD-1單抗產品的市場開發及產品推廣和銷售;及(ii)集團將向天晴康方收取銷售及推廣費用,並向天晴康方採購PD-1單抗產品。
該PD-1單抗產品由集團與中山康方聯合開發,早前已獲得中國國家藥品監督管理局批準上巿,用於治療至少經過二線系統化療復發或難治性經典型霍奇金淋巴瘤患者。派安普利單抗獨家銷售協議的簽訂,使PD-1單抗產品可充分利用本集團遍及全國的銷售網絡和資源以及豐富的產品推廣經驗,這將有利於加快PD-1單抗產品的商業化進程,可惠及更多的國內患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.